<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393380</url>
  </required_header>
  <id_info>
    <org_study_id>435</org_study_id>
    <secondary_id>U54HL081030-02</secondary_id>
    <nct_id>NCT00393380</nct_id>
    <nct_alias>NCT00579722</nct_alias>
  </id_info>
  <brief_title>Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor</brief_title>
  <official_title>A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The EMMES Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the addition of parathyroid hormone after a
      sequential cord blood transplant will improve engraftment, which is the ability of the
      transplanted stem cells to grow and to successfully begin producing new blood cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II, single stage study, participants will include 40 adults who are candidates
      for a hematopoietic stem cell transplant. All participants will undergo a sequential cord
      blood transplant using a well-known myeloablative regimen of fludarabine, cyclophosphamide,
      and total body irradiation, which is appropriate for those individuals who are likely to
      benefit from an ablative regimen. Tacrolimus will be combined with mycophenolate mofetil
      (MMF) for the graft-versus-host disease (GVHD) prophylaxis regimen. Parathyroid hormone (PTH)
      will be added to this regimen in an attempt to improve engraftment. PTH is an approved drug
      with minimal side effects in individuals with osteoporosis; the dose of PTH has been
      determined from a phase I study in individuals with hematologic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped because of toxicity concerns.
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Time to Neutrophil Engraftment (Defined as an Absolute Neutrophil Count [ANC] Greater Than 500)</measure>
    <time_frame>Statistic is calculated at Day 42 but ANC counts are measured daily up through discharge.</time_frame>
    <description>Median time to neutrophil engraftment (defined as an absolute neutrophil count [ANC] greater than 500)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Acute GVHD Grades II-IV at Day 100</measure>
    <time_frame>Measured at Day 100</time_frame>
    <description>Cumulative Incidence of Acute GVHD Grades II-IV at day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Chronic GVHD</measure>
    <time_frame>Measured at 2 years</time_frame>
    <description>Cumulative Incidence of Chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Engraftment (Greater Than 20,000)</measure>
    <time_frame>Measured at Day 180</time_frame>
    <description>Platelet engraftment (greater than 20,000)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>100-day Transplant-related Mortality</measure>
    <time_frame>Measured at Day 100</time_frame>
    <description>100-day transplant-related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Incidence of Relapse</measure>
    <time_frame>Measured at 2 years</time_frame>
    <description>Cumulative Incidence of Relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Measured at 2 years</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Measured at 1 year</time_frame>
    <description>Disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <condition>Anemia, Aplastic</condition>
  <condition>Myelofibrosis</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <condition>Leukemia, Myelocytic, Acute</condition>
  <condition>Leukemia, Lymphocytic, Acute</condition>
  <arm_group>
    <arm_group_label>Parathyroid Hormone (teriparatide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parathyroid Hormone (teriparatide)</intervention_name>
    <description>Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC&gt;2000/microL: PTH 100 mcg</description>
    <arm_group_label>Parathyroid Hormone (teriparatide)</arm_group_label>
    <other_name>Parathyroid hormone</other_name>
    <other_name>PTH</other_name>
    <other_name>teriparatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of the following diagnoses:

               1. Chronic myelogenous leukemia (CML) accelerated phase or second stable phase;
                  individuals in the first chronic phase are eligible if they have resistance to
                  imatinib

               2. Myelodysplasia

               3. Aplastic anemia that is not responding to immunosuppressive therapy

               4. Myelofibrosis, either primary or secondary to polycythemia vera

               5. Relapsed lymphoma or Hodgkin's disease

               6. Stage III/IV chronic lymphocytic leukemia (CLL), relapsed after or refractory to
                  at least one fludarabine containing regimen

               7. Acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL) in
                  complete remission (CR) 2 or greater, or CR 1 with high risk features

          -  No prior autologous stem cell transplant

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than 2

          -  Lack of 6/6 or 5/6 matched related donor OR lack of 10/10 matched unrelated donor OR
             no available donor in the appropriate time frame to perform a potentially curative
             stem cell transplant

          -  Diffusing capacity of the lung for carbon monoxide (DLCO) greater than 50% of
             predicted value

          -  Left ventricular ejection fraction (LVEF) greater than 50% of predicted value

          -  Calcium levels less than 10.5 mg/dl

          -  Phosphate levels greater than 1.6 mg/dl

        Exclusion Criteria:

          -  Heart disease, as determined by symptomatic congestive heart failure, radionuclide
             ventriculogram (RVG), or echocardiogram-determined LVEF of less than 50%, active
             angina pectoris, or uncontrolled high blood pressure

          -  Pulmonary disease, as determined by severe chronic obstructive lung disease,
             symptomatic restrictive lung disease, or corrected DLCO of less than 50% of predicted
             value

          -  Kidney disease, as determined by serum creatinine levels greater than 2.0 mg/dl

          -  Liver disease, as determined by serum bilirubin levels greater than 2.0 mg/dl (except
             in the case of Gilbert's syndrome or hemolytic anemia in which the bilirubin can be
             elevated greater than 2.0mg/dl), SGOT or SGPT greater than 3 times the upper limit of
             normal

          -  Neurologic disease, as determined by symptomatic leukoencephalopathy, active central
             nervous system (CNS) cancer, or other neuropsychiatric abnormalities that may prevent
             transplantation (previous CNS cancer and presently in CR is acceptable)

          -  HIV antibodies

          -  Uncontrolled infection

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen K. Ballen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Antin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Avigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth J Shpall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Colleen Delaney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ram Kamble, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarzyna Jamieson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip McCarthy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Ball, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Maziarz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2006</study_first_posted>
  <results_first_submitted>November 6, 2012</results_first_submitted>
  <results_first_submitted_qc>November 6, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 7, 2012</results_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelogenous Leukemia, Chronic</keyword>
  <keyword>Myelodysplasia</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <keyword>Umbilical Cord Blood Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirteen patients were enrolled on the study between October 25, 2006 and March 27, 2008 from three centers. Dana Farber Cancer Institute enrolled 10 patients, University of Florida enrolled 2 patients and Massachusetts General Hospital enrolled 1 patient.</recruitment_details>
      <pre_assignment_details>Thirteen patients who were enrolled proceeded to the cord blood transplant.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Parathyroid Hormone (Teriparatide)</title>
          <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Parathyroid Hormone (Teriparatide)</title>
          <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Median Age at Transplant</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="25" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <description>Race among patients transplanted.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Time to Neutrophil Engraftment (Defined as an Absolute Neutrophil Count [ANC] Greater Than 500)</title>
        <description>Median time to neutrophil engraftment (defined as an absolute neutrophil count [ANC] greater than 500)</description>
        <time_frame>Statistic is calculated at Day 42 but ANC counts are measured daily up through discharge.</time_frame>
        <population>13 patients received the transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Neutrophil Engraftment (Defined as an Absolute Neutrophil Count [ANC] Greater Than 500)</title>
          <description>Median time to neutrophil engraftment (defined as an absolute neutrophil count [ANC] greater than 500)</description>
          <population>13 patients received the transplant.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="19" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Acute GVHD Grades II-IV at Day 100</title>
        <description>Cumulative Incidence of Acute GVHD Grades II-IV at day 100</description>
        <time_frame>Measured at Day 100</time_frame>
        <population>13 patients were transplanted</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Acute GVHD Grades II-IV at Day 100</title>
          <description>Cumulative Incidence of Acute GVHD Grades II-IV at day 100</description>
          <population>13 patients were transplanted</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="10.3" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Chronic GVHD</title>
        <description>Cumulative Incidence of Chronic GVHD</description>
        <time_frame>Measured at 2 years</time_frame>
        <population>13 patients were transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Chronic GVHD</title>
          <description>Cumulative Incidence of Chronic GVHD</description>
          <population>13 patients were transplanted.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="8.1" upper_limit="68.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Engraftment (Greater Than 20,000)</title>
        <description>Platelet engraftment (greater than 20,000)</description>
        <time_frame>Measured at Day 180</time_frame>
        <population>13 patients were transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Engraftment (Greater Than 20,000)</title>
          <description>Platelet engraftment (greater than 20,000)</description>
          <population>13 patients were transplanted.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" lower_limit="17.0" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>100-day Transplant-related Mortality</title>
        <description>100-day transplant-related mortality</description>
        <time_frame>Measured at Day 100</time_frame>
        <population>13 patients were transplanted</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>100-day Transplant-related Mortality</title>
          <description>100-day transplant-related mortality</description>
          <population>13 patients were transplanted</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Incidence of Relapse</title>
        <description>Cumulative Incidence of Relapse</description>
        <time_frame>Measured at 2 years</time_frame>
        <population>13 patients were transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Incidence of Relapse</title>
          <description>Cumulative Incidence of Relapse</description>
          <population>13 patients were transplanted.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="0.0" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall Survival</description>
        <time_frame>Measured at 2 years</time_frame>
        <population>13 patients were transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival</description>
          <population>13 patients were transplanted.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="14.1" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival</description>
        <time_frame>Measured at 1 year</time_frame>
        <population>13 patients were transplanted.</population>
        <group_list>
          <group group_id="O1">
            <title>Parathyroid Hormone (Teriparatide)</title>
            <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Disease-free survival</description>
          <population>13 patients were transplanted.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="14.1" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Parathyroid Hormone (Teriparatide)</title>
          <description>Parathyroid hormone after double umbilical cord blood transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Death</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed prematurely due to early mortality and lack of efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adam Mendizabal, Statistician</name_or_title>
      <organization>The EMMES Corporation</organization>
      <phone>301-251-1161 ext 221</phone>
      <email>amendizabal@emmes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

